← Back to Clinical Trials
Recruiting NCT04444349

NCT04444349 Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04444349
Status Recruiting
Phase
Sponsor Nanjing Medical University
Condition Cardiovascular Disease
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2021-02-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Coenzyme Q10Standard Medical Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2021-02-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cardiovascular diseases are the leading causes of death and prescription drug use. Research on certain dietary supplements looks promising as a way to help reduce risk factors. Previous studies showed that CoQ10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed. The overall objective of this study is to determine if supplementing with CoQ10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.

Eligibility Criteria

Inclusion Criteria: * Adult men and women * Who receive cardiovascular surgery * Agree to participate in the surgery and sign the informed consent form Exclusion Criteria: * Pregnant or planning on getting pregnant during the study * Contain a minimum of 2 traits of metabolic syndrome * Refused to participate in the surgery and refused informed consent

Contact & Investigator

Central Contact

Hong Liu, MD

✉ dr.hongliu@foxmail.com

📞 8618801281613

Frequently Asked Questions

Who can join the NCT04444349 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04444349 currently recruiting?

Yes, NCT04444349 is actively recruiting participants. Contact the research team at dr.hongliu@foxmail.com for enrollment information.

Where is the NCT04444349 trial being conducted?

This trial is being conducted at Beijing, China, Guangzhou, China, Nanjing, China, Chengdu, China.

Who is sponsoring the NCT04444349 clinical trial?

NCT04444349 is sponsored by Nanjing Medical University. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology